Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ILK | Q13418 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 2/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132051 | 0.82 | MAPK1 (0.83) | CYP3A4RPS6KA3MAPK14MAPK1NPSR1 | |
| SCHEMBL1016030 | 0.80 | MAPK14 (0.53) | CYP3A4RPS6KA3MAPK14MAPK1NPSR1 | |
| SCHEMBL3656155 | 0.78 | MAPK14 (0.58) | CYP3A4RPS6KA3MAPK14MAPK1NPSR1 | |
| SCHEMBL1017850 | 0.77 | BRAF (0.48) | CYP3A4MAPK14RAF1MAPK13BRAF | |
| SCHEMBL14519415 | 0.77 | RAF1 (0.49) | CYP3A4RPS6KA3MAPK14RAF1MAPK13 | |
| SCHEMBL3655297 | 0.76 | PIK3CD (0.57) | CYP3A4RPS6KA3MAPK14MAPK1NPSR1 | |
| SCHEMBL6076585 | 0.73 | MAPK14 (1.00) | RPS6KA3MAPK14MAPK1NPSR1ILK | |
| SCHEMBL6179977 | 0.73 | MAPK14 (1.00) | RPS6KA3MAPK14MAPK1NPSR1ILK | |
| SCHEMBL5820038 | 0.72 | MAPK1 (1.00) | CYP3A4RPS6KA3MAPK14MAPK1NPSR1 | |
| SCHEMBL1138550 | 0.72 | CYP17A1 (0.70) | CYP3A4MAPK14RAF1MAPK13BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271649-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | Wyeth LLC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2203453-A1 | PYRAZOLO[5, 1-C] [1,2,4]TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009111260-A1 | PHENYLSULFONAMIDE-SUBSTITUTED, PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009108838-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009039387-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | WYETH (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082354-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082354-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | RAF1, BRAF, ARAF | CYP3A4 1854/4885RPS6KA3 534/4885MAPK14 242/4885 |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | BRAF, RAF1, ARAF | CYP3A4 2482/4885RPS6KA3 399/4885MAPK14 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.